Mortality and other adverse outcomes in patients with type 2 diabetes mellitus admitted for COVID-19 in association with glucose-lowering drugs: a nationwide cohort study
Pérez-Belmonte et al.
, Mortality and other adverse outcomes in patients with type 2 diabetes mellitus admitted for COVID-19 in..
, BMC Medicine, doi:10.1186/s12916-020-01832-2
Retrospective 2,666 type 2 diabetes COVID-19 patients in Spain, showing higher mortality with existing metformin use (not statistically significant).
risk of death, 10.4% higher, RR 1.10, p = 0.48, treatment 79 of 249 (31.7%), control 79 of 249 (31.7%), adjusted per study, odds ratio converted to relative risk, mixed effect logistic regression, propensity score matching.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Pérez-Belmonte et al., 16 Nov 2020, retrospective, propensity score matching, Spain, peer-reviewed, 26 authors.
Abstract: Pérez-Belmonte et al. BMC Medicine
Mortality and other adverse outcomes in
patients with type 2 diabetes mellitus
admitted for COVID-19 in association with
glucose-lowering drugs: a nationwide
Luis M. Pérez-Belmonte1*, José David Torres-Peña2,3, María D. López-Carmona1, M. Mar. Ayala-Gutiérrez1,
Francisco Fuentes-Jiménez2,3, Lucía Jorge Huerta4, Jaime Alonso Muñoz5, Manuel Rubio-Rivas6, Manel Madrazo7,
Marcos Guzmán Garcia8, Beatriz Vicente Montes9, Joaquim Fernández Sola10, Javier Ena11, Ruth Gonzalez Ferrer12,
Carmen Mella Pérez13, Carlos Jorge Ripper14, Jose Javier Napal Lecumberri15, Iris El Attar Acedo16,
Susana Plaza Canteli17, Sara Fuente Cosío18, Francisco Amorós Martínez19, Begoña Cortés Rodríguez20,
Pablo Pérez-Martínez2,3*, José Manuel Ramos-Rincón21, Ricardo Gómez-Huelgas1 and for the SEMI-COVID-19
Background: Limited evidence exists on the role of glucose-lowering drugs in patients with COVID-19. Our main
objective was to examine the association between in-hospital death and each routine at-home glucose-lowering
drug both individually and in combination with metformin in patients with type 2 diabetes mellitus admitted for
COVID-19. We also evaluated their association with the composite outcome of the need for ICU admission, invasive
and non-invasive mechanical ventilation, or in-hospital death as well as on the development of in-hospital
complications and a long-time hospital stay.
(Continued on next page)
* Correspondence: email@example.com; firstname.lastname@example.org
A complete list of the SEMI-COVID-19 Network members is provided in the
Internal Medicine Department, Regional University Hospital of Málaga,
Biomedical Research Institute of Málaga (IBIMA), University of Málaga (UMA),
Avenida de Carlos Haya, s/n, 29010 Málaga, Spain
Lipids and Atherosclerosis Unit, Department of Internal Medicine,
Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofia
University Hospital, University of Cordoba, Córdoba, Spain
Full list of author information is available at the end of the article
© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
Pérez-Belmonte et al. BMC Medicine
Page 2 of 10
(Continued from previous page)
Methods: We selected all patients with type 2 diabetes mellitus in the Spanish Society of Internal Medicine’s
registry of COVID-19..
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC
provide treatment protocols.